Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | KDM3B | Q7LBC6 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | DPYD | Q12882 | 5/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | THPO | P40225 | 1/20 | 0.43 |
| ▸ | MTOR | P42345 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | HBB | P68871 | 1/20 | 0.43 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28568534 | 0.83 | KMT2A (0.35) | GAAKDM3BLMNADPYDALDH1A1 | |
| SCHEMBL127493 | 0.83 | KDM3B (0.64) | GAAKDM3BLMNADPYDALDH1A1 | |
| Water SCHEMBL4487821 | 0.81 | KDM3B (0.62) | GAAKDM3BLMNADPYDALDH1A1 | |
| Hydrochloric Acid SCHEMBL11439523 | 0.81 | KDM3B (0.62) | GAAKDM3BLMNADPYDALDH1A1 | |
| SCHEMBL891086 | 0.80 | GAA (0.45) | GAAKDM3BLMNADPYDALDH1A1 | |
| SCHEMBL28535407 | 0.80 | CRBN (0.53) | GAAKDM3BLMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL18640387 | 0.77 | KMT2A (0.44) | GAALMNADPYDALDH1A1SMN1; SMN2 | |
| SCHEMBL190958 | 0.77 | GAA (0.50) | GAAKDM3BLMNADPYDALDH1A1 | |
| SCHEMBL6524027 | 0.77 | GAA (0.50) | GAAKDM3BLMNADPYDALDH1A1 | |
| SCHEMBL1210894 | 0.77 | GAA (0.50) | GAAKDM3BLMNADPYDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 865 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150211004-A1 | RNAI-BASED THERAPIES FOR CARDIOMYOPATHIES, MUSCULAR DYSTROPHIES AND LAMINOPATHIES | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2015-07-30 | — | — | US | claimed |
| EP-2838541-A1 | RNAI-BASED THERAPIES FOR CARDIOMYOPATHIES, MUSCULAR DYSTROPHIES AND LAMINOPATHIES | Agency For Science, Technology And Research (SG) | 2015-02-25 | — | — | EP | claimed |
| WO-2013158046-A1 | RNAI-BASED THERAPIES FOR CARDIOMYOPATHIES, MUSCULAR DYSTROPHIES AND LAMINOPATHIES | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2013-10-24 | — | — | WO | claimed |
| WO-2026106695-A1 | TARGETED NANOPARTICLES ENCAPSULATING WATER-SOLUBLE THERAPEUTICS, METHODS OF PRODUCTION, AND USE | OPTIMEOS LIFE SCIENCES, INC. (US) | 2026-05-21 | — | — | WO | disclosed |
| WO-2026103877-A1 | LIPID COMPOUND AND LIPID NANOPARTICLE COMPOSITION | 中生复诺健生物科技(上海)有限公司 | 2026-05-21 | — | — | WO | disclosed |
| WO-2026098357-A1 | FREEZE-DRIED NUCLEIC ACID-LOADED LIPID NANOPARTICLE AND RECONSTITUTION METHOD THEREOF | KUDO BIOTECHNOLOGY, INC. (US) | 2026-05-15 | — | — | WO | disclosed |
| US-20260130987-A1 | VACCINATION AGAINST PNEUMOCCOCAL AND COVID-19 INFECTIONS | PFIZER INC. (US) | 2026-05-14 | — | — | US | disclosed |
| WO-2026088119-A1 | LIPIDATED TLR7/8 MODULATORS AS ADJUVANTS AND USES THEREOF | PFIZER INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| US-20260109977-A1 | MODIFIED RNA FOR INCREASING PROTEIN EXPRESSION | TRILINK BIOTECHNOLOGIES, LLC (US) | 2026-04-23 | — | — | US | disclosed |
| EP-4728076-A1 | METHOD FOR STABILIZING RNA | Pfizer Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| US-12606814-B2 | Oligonucleotide probes and uses thereof | CARIS SCIENCE, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| US-20050123977-A1 | Assay and treatment | LUDWIG INSTITUTE FOR CANCER RESEARCH | 2005-06-09 | — | — | US | disclosed |
| WO-2005051431-A1 | COLLOIDAL DELIVERY SYSTEM FOR BIOLOGICAL THERAPEUTIC AGENTS | THE UNIVERSITY OF YORK (GB) | 2005-06-09 | — | — | WO | disclosed |
| EP-1509624-A2 | MET/FRET BASED METHOD OF TARGET NUCLEIC ACID DETECTION WHEREBY THE DONOR/ACCEPTOR MOIETIES ARE ON COMPLEMENTARY STRANDS | SECRETARY, DEPARTMENT OF ATOMIC ENERGY (IN) | 2005-03-02 | — | — | EP | disclosed |
| WO-2005014645-A2 | PEDF-R RECEPTOR AND USES | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2005-02-17 | — | — | WO | disclosed |
| US-20040235171-A1 | Silencing of gene expression by sirna | UNIVERSITY OF YORK, THE (GB) | 2004-11-25 | — | — | US | disclosed |
| WO-2003102239-A2 | MET/FRET BASED METHOD OF TARGET NUCLEIC ACID DETECTION WHEREBY THE DONOR/ACCEPTOR MOIETIES ARE ON COMPLEMENTARY STRANDS | SECRETARY, DEPARTMENT OF ATOMIC ENERGY (IN) | 2003-12-11 | — | — | WO | disclosed |
| US-20030059417-A1 | Methods and compositions for diagnosing and treating disorders involving angiogenesis | SHEPPARD MICHAEL G (AU) | 2003-03-27 | — | — | US | disclosed |
| WO-2002077219-A1 | NOVEL HUMAN ASPARAGINASES AND POLYNUCLEOTIDES ENCODING THE SAME | LEXICON GENETICS INCORPORATED (US) | 2002-10-03 | — | — | WO | disclosed |
| EP-1197550-A2 | Methods and compositions for diagnosing and treating disorders involving angiogenesis | Pfizer Products Inc. (US) | 2002-04-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260109977-A1 | MODIFIED RNA FOR INCREASING PROTEIN EXPRESSION | RNGTT, RNMT, UPF1 | GAA 3364/4885KDM3B 721/4885LMNA 337/4885 |
| US-20260130987-A1 | VACCINATION AGAINST PNEUMOCCOCAL AND COVID-19 INFECTIONS | SARS1, CD14, PYCARD | GAA 3633/4885KDM3B 4627/4885LMNA 2200/4885 |
| US-12606814-B2 | Oligonucleotide probes and uses thereof | CD63, FLT4, NCL | GAA 3273/4885KDM3B 4108/4885LMNA 1587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.